Gonadal Dysgenesis
A number of syndromes with defective gonadal developments such as streak GONADS and dysgenetic testes or ovaries. The spectrum of gonadal and sexual abnormalities is reflected in their varied sex chromosome (SEX CHROMOSOMES) constitution as shown by the karyotypes of 45,X monosomy (TURNER SYNDROME); 46,XX (GONADAL DYSGENESIS, 46XX); 46,XY (GONADAL DYSGENESIS, 46,XY); and sex chromosome MOSAICISM; (GONADAL DYSGENESIS, MIXED). Their phenotypes range from female, through ambiguous, to male. This concept includes gonadal agenesis.
Subtype terms (5)
More specific conditions that are subtypes of Gonadal Dysgenesis in the MeSH hierarchy.
- Gonadal Dysgenesis, 46,XX
- Gonadal Dysgenesis, 46,XY
- Gonadal Dysgenesis, Mixed
- Sexual Infantilism
- Turner Syndrome
15 drugs (12 approved, 3 experimental)
Drugs by status
Phase 2 trials (1)
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (14)
- Ipsen
- Dong-A Pharmaceutical
- National Institute of Neurological Disorders and Stroke (NINDS)
- Ajou University
- Korea University
- Seoul National University
- Yonsei University
- Chonbuk National University
- University of Ulsan
- Catholic University of Korea
- Kyungpook University
- Chonnam National University
- Ferring
- Pusan National University
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (3)